All News GlobeImmune, Inc.

Equities

GBIM

US37957B1008

Market Closed - OTC Markets Other stock markets 18:43:20 14/03/2024 GMT			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-.--%

2022	Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital announced an offer to acquire 12.2% stake in GlobeImmune, Inc. for $7,000.	CI
2017	NantCell, Inc. Exercises Option for Licensing Agreement with GlobeImmune, Inc. for GI-6100	CI

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Alternative Liquidity Index Announces Offer to Purchase Shares in GlobeImmune, Inc.	06/05/22	AQ
Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital announced an offer to acquire 12.2% stake in GlobeImmune, Inc. for $7,000.	05/05/22	CI
NantCell, Inc. Exercises Option for Licensing Agreement with GlobeImmune, Inc. for GI-6100	30/08/17	CI
NantCell, Inc. Enters into Licensing Agreement with GlobeImmune, Inc. for GI-4000	30/08/17	CI
NantCell, Inc. Enters into Licensing Agreement with GlobeImmune, Inc. for GI-6207 and GI-6301	30/08/17	CI
GlobeImmune, Inc. announced a financing transaction	19/03/17	CI
Gilead Sciences, Inc. Terminates the Collaboration and License Agreement with GlobeImmune	17/11/16	CI
GlobeImmune Inc. Announces Management and Board Changes	17/11/16	CI
GlobeImmune Inc.(OTCPK:GBIM) dropped from S&P TMI Index	25/07/16	CI
GlobeImmune Inc.(OTCPK:GBIM) dropped from NASDAQ Composite Index	24/07/16	CI
Globeimmune, Inc Announces Financial Results for the First Quarter Ended March 31, 2016	12/05/16	CI
GlobeImmune Seeks Alternatives	12/05/16	CI
GlobeImmune Inc.(NasdaqCM:GBIM) dropped from CRSP US Total Market Index	21/03/16	CI
GlobeImmune Inc. Reports Earnings Results for the Year Ended December 31, 2015; Provides Update on Clinical Programs	16/03/16	CI
GlobeImmune Inc. Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	13/11/15	CI
GlobeImmune Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2015	14/08/15	CI
GlobeImmune Weighing A Potential Sale	14/08/15	CI
GlobeImmune Explores Strategic Alternatives	13/08/15	CI
Globeimmune, Inc. Enters into License Agreement with Celgene Corporation	04/08/15	CI
Kirk Christoffersen to Leave GlobeImmune Inc. as Vice President, Corporate Development, Effective Aug. 3, 2015	17/07/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News GlobeImmune, Inc.

Equities

GBIM

US37957B1008

All News

Filters